Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
January 04, 2018 08:30 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for tucatinib, an...
Medable Inc. to Present at the Biotech Showcase Annual Conference on January 10, 2018
January 03, 2018 10:00 ET
|
Medable
PALO ALTO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Medable Inc., the leading app and analytics platform for healthcare, today announced that Medable CEO Dr. Michelle Longmire will talk about “The...
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
January 02, 2018 08:30 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it received a product-specific pediatric...
GT Biopharma, Inc. Files Application for NASDAQ Capital Market Listing
December 18, 2017 10:47 ET
|
GT Biopharma, Inc.
WASHINGTON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- GT Biopharma Inc. (OTCQB:GTBP) today announced that the Company has filed an application to list its common stock on the NASDAQ Capital Market. GT...
IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 29, 2017
December 18, 2017 08:00 ET
|
India Globalization Capital
BETHESDA, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), adjourned again the voting for Proposals Three and Four from its Notice of Annual Meeting of...
BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)
December 14, 2017 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index
December 13, 2017 08:35 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, today announced that it has been selected for addition to the...
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
December 07, 2017 16:05 ET
|
Cascadian Therapeutics, Inc.
SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of...
BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China
December 04, 2017 07:00 ET
|
BeyondSpring, Inc.
NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority
November 30, 2017 09:58 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...